Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Monopar Therapeutics Inc (MNPR)
:MNPR
RESEARCH TOOLSreports
Holding MNPR?
Track your performance easily
MNPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.55 - $38.50
Previous CloseN/A
Volume23.12K
Average Volume (3M)78.05K
Market Cap
$186.01M
Enterprise Value$17.71M
Total Cash (Recent Filing)$2.07M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 20, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding6,102,528
10 Day Avg. Volume47,999
30 Day Avg. Volume78,048
Standard Deviation0.40
R-Squared0.03
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-33.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.15
Forecast
1Y Price Target
$43.67Price Target Upside43.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Monopar Therapeutics Inc News
PremiumCompany Announcements
Monopar Therapeutics Achieves Milestone in Cancer Treatment
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessALXN-1840 successfully completed a randomized Phase 3 study, showing significant improvement in copper mobilization compared to standard-of-care therapies.
Research And DevelopmentMonopar Therapeutics is developing uPAR-targeted radiotherapeutics for oncology, which is seen as a unique and compelling development program.
Strategic AcquisitionThe in-licensure of ALXN1840 from AstraZeneca is viewed as a strategic acquisition, and the treatment is considered best-in-class for Wilson disease.
Bears Say
Failed Clinical TrialsTwo Phase 2 studies failed to demonstrate how ALXN-1840 clears copper from the body, leading to AstraZeneca terminating the development program.
Financial CommitmentMNPR will pay Alexion $4M upfront in cash and a 9.9% ownership stake, with potential payments up to $94M upon achieving certain milestones.
Limited DataWhile the data only came from one patient, it provides early clinical validation of uPAR, MNPR's target.
---
Ownership Overview
17.00% Insiders
0.34% Mutual Funds
― Other Institutional Investors
82.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $1.54 and its highest was $38.50 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is $186.01M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is Mar 20, 2025 which is in 61 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on Nov 08, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.995 by $0.625.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate is -0.36.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 6,102,528 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.995. Following the earnings report the stock price went up 7.311%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in MNPR
---
Monopar Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.67 (43.27% Upside)
$43.67 (43.27% Upside)
Blogger Sentiment
Bullish
MNPR Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $25.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 42.1%
Last 30 Days ▲ 42.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1372.46%
12-Months-Change
Fundamentals
Return on Equity
-112.04%
Trailing 12-Months
Asset Growth
-29.37%
Trailing 12-Months
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
---
MNPR Stock 12 Month Forecast
Average Price Target
$43.67
▲(43.27% Upside)
Technical Analysis
Eloxx Pharmaceuticals
―
Cellectar Biosciences
―
Genprex
―
Cardiff Oncology
―
ADMA Biologics
―
Traws Pharma
―
Best Analysts Covering MNPR
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+137.36%
reiterated a buy rating 2 months ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +137.36% per trade.
---